Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Godavari Biorefineries receives patent from CNIPA
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
To streamline complex medical writing workflows with GenAI
Subscribe To Our Newsletter & Stay Updated